SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -
- Received U.S..
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.
Soleno Therapeutics (SLNO) Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.